Ibrexafungerp
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Invasive Candidiasis
Conditions
Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Trial Timeline
Apr 1, 2017 → Aug 25, 2023
NCT ID
NCT03059992About Ibrexafungerp
Ibrexafungerp is a phase 3 stage product being developed by Scynexis for Invasive Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03059992. Target conditions include Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06954493 | Phase 1 | Completed |
| NCT05668429 | Phase 1 | Completed |
| NCT05399641 | Phase 3 | Completed |
| NCT03059992 | Phase 3 | Completed |
Competing Products
20 competing products in Invasive Candidiasis